GeneDx reported Q4 FY2025 revenue of USD 121 million (+27%), including exome and genome test revenue of USD 104 million (+32%). Q4 adjusted gross margin was 71% (GAAP: 70%), while adjusted net income was USD 4.4 million and GAAP net loss was USD 17.7 million. Exome and genome test result volume in Q4 rose to 27,761 (+34.3%). For FY2025, GeneDx posted revenue of USD 427.5 million (+41%) and exome and genome test revenue of USD 360.3 million (+54%). FY adjusted gross margin was 71% (GAAP: 70%), with adjusted net income of USD 41.8 million and GAAP net loss of USD 21 million. Cash, cash equivalents, marketable securities and restricted cash totaled USD 172.3 million at December 31, 2025. The company reaffirmed FY2026 guidance for revenue of USD 540 million to USD 555 million, exome and genome revenue growth of 33% to 35%, adjusted gross margin of at least 70%, and positive adjusted net income. Business updates included the launch of GeneDx Infinity (over 1 million exomes and genomes, more than 2.5 million genetic tests, and over 8 million phenotypic data points), expansion into general pediatrics and prenatal diagnostics (GenomeDx Prenatal), rollout of ultraRapid genome sequencing with turnaround as soon as 48 hours, expanded Medicaid coverage in 8 new states (bringing pediatric outpatient exome/genome coverage to 38 states and NICU rapid genome coverage to 17), and completion of the Fabric Genomics acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602230630BIZWIRE_USPR_____20260223_BW454462) on February 23, 2026, and is solely responsible for the information contained therein.